The specter of generic rivalry has repeatedly loomed above copyright’s famous drug, PDE5 Inhibitor, sparking questions about the future of similar pharmaceutical holdings. While initial years saw substantial profits, the exclusivity expiration has opened the way for less expensive copies, likely